Literature DB >> 27712764

Performing Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease.

Jeremy D Waldram1, Ronald A Simon2.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) is characterized by chronic rhinosinusitis with nasal polyps, asthma, and reactions to cyclooxygenase-1-inhibiting drugs. This condition is often refractory to standard medical treatments and results in aggressive nasal polyposis that often requires multiple sinus surgeries. Aspirin desensitization followed by daily aspirin therapy is an important treatment option, and its efficacy has been validated in multiple research studies. Aspirin desensitization is not without risk, but specific protocols and recommendations exist to mitigate the risk. Most patients with AERD can undergo aspirin desensitization in an outpatient setting under the supervision of an allergist.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AERD; AERD diagnosis; AERD treatment; Aspirin; Desensitization

Mesh:

Substances:

Year:  2016        PMID: 27712764     DOI: 10.1016/j.iac.2016.06.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  4 in total

Review 1.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

2.  Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.

Authors:  Hannah Wangberg; Samantha R Spierling Bagsic; Joshua M Levy; Andrew White
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-15       Impact factor: 5.426

3.  Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: A systematic review of the literature and meta-analysis.

Authors:  Isabel Eraso; Saveria Sangiovanni; Eliana I Morales; Liliana Fernández-Trujillo
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

4.  Clinical and Immunological Efficacy of Aspirin Desensitization in Nasal Polyp Patients with Aspirin-Exacerbated Respiratory Disease.

Authors:  Negar Mortazavi; Hossein Esmaeilzadeh; Mohammad Abbasinazari; Delara Babaie; Soheila Alyasin; Hesamodin Nabavizadeh; Elmira Esmailzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.